NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Ocular Therapeutix, Inc. OCUL
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$52.0M
▼ 18.5% vs FY2024
EPS · FY25
$-1.42
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-54.9%
Net margin · FY25
-511.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 52.0M
Revenue, FY2025 · full 14-year series below
Revenue
Net income
The company lost 512 cents on every revenue dollar this year.
Per share
USD -1.42
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-54.9%
Return on equity, FY2025
ROE
Operating margin-519.8%
Net margin-511.9%
Return on assets-42.0%
Each USD of equity lost 55 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+24.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.3%
+24.4%
+40.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.22B
Shares outstanding, FY2025
Change, 5 years+184.1%
Change, 10 years—
The share count grew 184% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 808.1M
total assets, end of FY2025
Total assetsUSD 808.1M
EquityUSD 654.3M
CashUSD 737.1M
Current ratio15.39×
Equity funds 81% of total assets.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
Operating income $B
−0.3
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.3
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.3
−0.2
−0.1
−0.1
−0.0
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.42
−1.22
−1.02
−0.97
−0.98
−2.56
−1.91
−1.57
−2.20
−1.80
−1.71
−2.69
−5.11
−5.60
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−54.9
−95.2
−127.6
−115.2
−8.0
−429.5
−535.7
−193.4
−162.2
−63.1
−53.6
·
·
·
Shares out B
0.22
0.16
0.11
0.08
0.08
0.08
0.05
0.04
0.03
0.03
0.02
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
40 of 40
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed